The short version of GABA-A modulation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
It can be argued that in the play Euripides portrays Medea as an enraged woman who kills her children to get revenge on her husband Jason because of his betrayal of their marriage. Medea is often cited as an example of the "madwoman in the attic" trope, in which women who defy societal norms are portrayed as mentally unstable. A competing interpretation is that Medea kills her children because she cares for them and worries about their well-being; once she commits to her plan to kill Creon and Jason's new bride, she knows her children are in danger of being murdered. This is not a paranoid fantasy; at this time in myth and history, helping one's friends and hurting one's enemies was considered a virtue. Thus, by their code of ethics, the Corinthians would do right to avenge their king and princess. (In another version of the myth, the people of Corinth kill her children to avenge the deaths of Creon and his daughter Glauce.) Conversely, a focus on Medea's rage leads to the interpretation that "Medea becomes the personification of vengeance, with her humanity 'mortified' and 'sloughed off'" (Cowherd, 129). Medea's heritage places her in a position more typically reserved for males. Hers is the power of the sun, appropriately symbolized by her great radiance, tremendous heat and boundless passion. In this view Medea is inhuman and her suffering is self-inflicted, just as Jason argues in his debate with her. And yet, if we see events through Medea's eyes, we view a wife intent on vengeance, and a mother concerned about her children's safety and quality of life.
Celia. A White witch, Nathan's former mentor with whom he was sent to live. She abused and locked him in a cage in the first book and Nathan has despised her ever since. Soul O'Brien. The leader of the Council of White Witches and Annalise's uncle. Mr. Wallend. An evil White witch who works for Soul and carries out gruesome experiments on Black witches. Annalise O'Brien. A White witch, some months older than Nathan. She is Nathan's initial primary love interest. She also ran from her cruel family upon learning of their tolerance for the White witches' cruelty. Jessica Byrn. Nathan's eldest half-sister who hates him, and a Hunter.
where R0 is the isotope ratio in the initial water vapor, Rr is the isotope ratio in the remaining water vapor after some condensation, f is the fraction of water vapor remaining in the air, and α is the liquid-vapor equilibrium fractionation factor (α=1+ε). The isotopic composition of the resulting precipitation (Rp) can be derived from the composition of the remaining vapor:
Allosteric activation by glucose-6-phosphate, which acts as an effector, stimulates glycogen synthase, and glucose-6-phosphate may inhibit the phosphorylation of glycogen synthase by cyclic AMP-stimulated protein kinase.
The first of these three means that the contact quadrilateral WXYZ is an orthodiagonal quadrilateral. A tangential quadrilateral is bicentric if and only if its inradius is greater than that of any other tangential quadrilateral having the same sequence of side lengths.
Sources: en.wikipedia.org
=== Force history dependence === The CMR phenomenon indicates that how long a bond can sustain force at a given level can depend on the history of force application prior to arriving at that force level. In other words, the "rate constant" of molecular dissociation at a constant force depends not only on the value of force at the current time but also on the prior force history the bond has experienced in the past. This has indeed been observed for interactions of P-selectin with PSGL-1 or anti-P-selectin antibody, L-selectin with PSGL-1, myosin with actin, integrin alpha V beta 3 with fibrinogen, and TCR with pMHC.
Arthur Guinness started brewing ales in 1759 at the St. James's Gate Brewery, Dublin. On 31 December 1759, he signed a 9,000 year lease at £45 per annum for the unused brewery, and it would become one of the largest in the British Empire. Arthur Guinness started selling porter in 1778. The first Guinness beers to use the term "stout" were Single Stout and Double Stout in the 1840s. Throughout the bulk of its history, Guinness produced only three variations of a single beer type: porter or stout (single, double or extra) and foreign stout for export. "Stout" originally referred to a beer's strength, but eventually shifted meaning toward body and colour. Porter was also referred to as "plain", as mentioned in the famous refrain of Flann O'Brien's poem "The Workman's Friend": "A pint of plain is your only man." Already one of the top-three British and Irish brewers, Guinness's sales soared from 350,000 barrels in 1868 to 779,000 barrels in 1876. In October 1886, Guinness became a public company and was averaging sales of 1.138 million barrels a year. This was despite the brewery's refusal to either advertise or offer its beer at a discount. Even though Guinness owned no public houses, the company was valued at £6 million and shares were 20 times oversubscribed, with share prices rising to a 60 per cent premium on the first day of trading. The breweries pioneered several quality control efforts.
==== Civil Protection ==== The Civil Protection is the Combine's primary law enforcement agency on Earth, whose ranks are drawn from unmodified, volunteering humans. Commonly referred to as "metrocops" or "CPs", Civil Protection personnel wear light body armor and face masks which resemble a modified PMK gas mask. They also have voice modifiers, masking their normal voices. They typically carry electroshock batons (named stun-sticks in the game) and pistols, and are occasionally equipped with submachine guns. The Civil Protection are frequently brutal in their methods, keeping the local populace in line via intimidation and violence. Interrogations, inspections, raids, random beatings, summary executions and acts of police brutality are all used as a means of policing their jurisdictions; the Civil Protection's methods are justified by their role as "protectors of the civilians' well-being". On the outskirts of City 17, the Civil Protection carry out constant patrols for escapees from the city. Civil Protection personnel are in constant contact with the Combine's Overwatch headquarters, which issues them objectives and situation updates. Upon the death of Civil Protection personnel, their armor detects that its wearer is no longer alive and automatically informs the Overwatch of the fatality.
Silencing systemin did not affect the ability of black nightshade to resist herbivory and, when competing against normal plants, silenced plants produced more above-ground biomass and berries. Upon herbivory, systemin was down-regulated in black nightshade in contrast to the other peptides which are up-regulated after herbivory. By contrast HypSys were up-regulated and activated the synthesis of protease inhibitors. The down-regulation of systemin was associated with increased root mass but did not decrease shoot mass, demonstrating that systemin can cause developmental changes as a result of herbivory, allowing the plant to tolerate, rather than directly resist attack. Tomato roots were also affected by tomato systemin, with root growth increasing at high tomato systemin concentrations. By allocating more resources to the roots, plants under attack are thought to store carbon and then use it to re-grow when the attack ends. Overexpressing AtPEP1 also increased root and shoot biomass in A. thaliana.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.